HLS Therapeutics to Commercialize Cholesterol-Lowering Drugs Nexletol and Nexlizet in Canada Under Esperion Therapeutics Agreement

HLS Therapeutics will commercialize two cholesterol-lowering medications, Nexletol and Nexlizet, in Canada, following an agreement with Esperion Therapeutics. The agreement grants HLS Therapeutics the rights to distribute and market the drugs within the Canadian market. Under the terms of the agreement, HLS Therapeutics gains commercial rights to Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe). These medications are oral, once-daily drugs designed to lower LDL-cholesterol. Esperion Therapeutics developed and manufactures the drugs. The partnership enables HLS Therapeutics to expand its portfolio in the cardiovascular therapeutic area.

Newsflash | Powered by GeneOnline AI
Date: May 9, 2025